Deadpool blend dosage and evidence

What is Deadpool blend?

How does Deadpool blend work?

People assume the three add up. Nobody has checked. BPC-157 seems to help blood vessels grow and tissue repair, as its own page explains, but that work is almost all in rats and mice. The piece of protein sold as TB-500 sticks to actin, a building block inside cells. KPV is a tiny tail cut from a skin hormone. In gut and immune cells it turns down swelling signals. No paper says what the three do when mixed. Nobody knows if their effects add up or just overlap. Nobody knows how three peptides that break down at different rates hold up in one vial in a fridge for weeks.

What have studies in people found about Deadpool blend?

None for the mix. Each of the three has its own thin record in people, and one of the three has nothing at all.

• BPC-157: FDA counted five studies in people, with fewer than 110 people in all. Two were only conference summaries. None lasted more than two weeks, and none gave it as a shot under the skin. A 2025 review found 35 of its 36 studies were in animals or in a dish. The one study in people looked back at 12 knee pain patients.
• TB-500: no study in people, by any route. A drug testing lab found the product is a seven building block piece of thymosin beta 4.
• KPV: no data in people at all. There is no listed trial. The record is mice with gut disease, cells in a dish, and a review that calls these peptides possible future treatments.
• The blend: no published study in people or animals, and no listed trial of the three together.

What this does not tell you: None of these three records says what happens when they go in together, at a mix a seller picked, on a timing that suits none of them, in a person instead of a rat. Nobody has tracked the side effects of the three together.

What do people who took Deadpool blend report?

This is what real people say happened to them, good and bad. Nobody measured it. A report cannot tell a real effect from the lift people get just from expecting it to work, from a diet or training change made at the same time, or from what was really in the vial. We still put it near the top. It is the next best thing to a study in people: what happens when real people use it, including what goes wrong.

• Less tendon and joint pain in the first few weeks, described the same way people describe BPC-157 alone.
• Gut problems calming down, which people credit to the KPV.
• Less stinging where the shot goes in than with the copper blends. People put this down to having no acidic copper in the mix.
• Confusion about what was really bought, because one name covers several mixes.
• No effect at all. This is common and rarely posted.

Sources: Peptide forums including r/peptides, vendor product pages and price-comparison listings. Uncontrolled self-reports from people usually running other compounds at the same time. Recorded as reports, not evidence.

The state of the research

The evidence, in charts

The studies we cite

• Review of studies2025
  Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review

  This review looked hard for BPC-157 studies and found almost none in people. Out of 36 studies it kept, 35 were in animals or in a dish. The one study in people looked back at 12 patients with knee pain who had the peptide put into the knee. 7 of the 12 said the pain eased for more than six months. There was no comparison group. The review says the peptide lasts under 30 minutes in the body.

  544 articles screened, 36 included, of which 35 were preclinical and one was clinical. That single clinical study was a retrospective series in which 7 of 12 patients reported relief beyond six months after intra-articular BPC-157 for unspecified chronic knee pain. The review puts the half-life at under 30 minutes.

  PMID 40756949 HSS Journal
• Review of studies2026
  FDA briefing document on BPC-157 for the July 2026 PCAC meeting

  FDA staff counted every study of BPC-157 in people. They found five, with fewer than 110 people in all. Two were only short conference summaries. None gave it for longer than two weeks. None gave it as a shot under the skin, which is how people use it. Staff found no good human data, and they found products on the market with the wrong label.

  FDA staff counted five published human studies of BPC-157 totalling fewer than 110 subjects, two of them meeting abstracts only, none dosing longer than two weeks, and none giving the peptide by subcutaneous injection. Staff found no adequate human data and mislabelled products in the market.

  Source FDA
• Review of studies2019
  Are melanocortin peptides future therapeutics for cutaneous wound healing?

  This is a skin doctors' review, not a test. It says KPV is a small piece of a skin hormone that keeps the calming effect but does not tan the skin. It suggests peptides like this could one day help wounds heal. The work it covers is computer models, cells in a dish, skin samples and animals. None of it is in people.

  A dermatology review describing KPV as a truncated alpha-MSH peptide that keeps the anti-inflammatory activity without the pigment-inducing activity, and proposing peptides of this class as future candidates for cutaneous wounds. The experimental approaches it surveys are in silico, in vitro, ex vivo and animal.

  PMID 30661264 Experimental Dermatology
• Animal study2008
  Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease

  In mice with an inflamed colon, KPV helped. The mice got better sooner and gained back more weight. Their colon tissue showed less swelling. This was two kinds of mouse gut disease, with KPV given on its own. It says nothing about people or about a blend.

  In two mouse colitis models KPV produced earlier recovery, greater body-weight regain, fewer inflammatory infiltrates and lower myeloperoxidase activity in colon tissue. Mice, KPV given alone, nothing here about a blend or about people.

  PMID 18092346 Inflammatory Bowel Diseases
• Lab (cells in a dish)2012
  Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential

  This is a lab test of what is really in a TB-500 vial. A drug testing lab for sport ran the product through its machines. It was not the full thymosin beta 4 protein, which has 43 building blocks. It was a small piece of it, just seven building blocks long. The studies people quote for TB-500 were done on the full protein.

  A doping control laboratory ran the TB-500 product through high performance liquid chromatography and high resolution mass spectrometry and identified the contents as Ac-LKKTETQ, the acetylated 17 to 23 fragment of thymosin beta 4. Seven amino acids, not the 43 amino acid protein the marketing names.

  PMID 22962027 Drug Testing and Analysis